A Case of Peritoneal Tuberculosis Developed after Infliximab Therapy for Refractory RA

Ji-Yeon Min, M.D. 1, So-Young Bang, M.D. 1, Seung-Yeon Min, M.D., Dae-Sung Lee, M.D., Bo-Sang Kim, M.D., Jeong-Eun Kim, M.D., Eun-Sung Lee, M.D., Ju-Yeon Pyo, M.D., Jang-Won Sohn, M.D., Tae-Hyung Kim, M.D., Hye-Soon Lee, M.D.

Departments of 1Internal Medicine and 2Pathology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea

Recently, interferon gamma releasing assay has been recommended to compensate the tuberculin skin test (TST) for screening for latent tuberculosis infection (LTBI). Although it improved the detection of LTBI before treatment with tumor necrosis factor blocker, its application to immune suppressed patients is limited. We report a case of peritoneal tuberculosis (TB) developed in a patient who tested positive for TST and QuantiFERON-TB Gold (QFT-G) before infliximab therapy, to emphasize the importance of monitoring during treatment. A 52-year-old woman presented with abdominal distension. She had been diagnosed with seropositive rheumatoid arthritis six years ago. She had started taking infliximab six months ago. All screening tests for TB were performed and the results of all were negative. At admission, the results of repeated TST and QFT-G tests were positive. Histopathological examination confirmed peritoneal TB. The patient started anti-TB therapy and the symptoms were relieved.

Key Words: Peritonitis, Tuberculous; Infliximab

Introduction

The tumor necrosis factor (TNF) blocker is known to be a promising treatment modality among patients with rheumatoid arthritis (RA) showing poor response to conventional therapy including disease modifying anti-rheumatic drugs (DMARDs). They improve the clinical outcome of RA dramatically, but also they might increase the risk of opportunistic infection. An increased susceptibility for tuberculosis (TB) or reactivation of latent TB, in particular, has been reported. Korea Food and Drug Association (KFDA) thus recommends that all patients should be screened for TB with tuberculin skin test (TST) and chest X-ray before undergoing the TNF blockers therapy. Recently, interferon gamma releasing assay (IGRA) is recommended to compensate the TST for screening the latent tuberculosis infection (LTBI). IGRA detects sensitization to Mycobacterium tuberculosis by measuring interferon gamma release in response to antigens representing M. tuberculosis. The QuantiFERON-TB gold (QFT-G) is the first IGRA approved by the FDA as an aid for diagnosing M. tuberculosis. In our case, the peritoneal tuberculosis developed in patient who tested both TST and QFT-G. In order to improve detecting the LTBI or newly developed TB, we strongly recommend to add monitoring guideline. Until now, no guideline has been established for monitoring TB during treatment with TNF blockers, we report this case with review to emphasize the importance of monitoring.
Case Report

A 52-year-old woman was admitted to the hospital with abdominal distention and low abdominal pain for the past four weeks. She did not have anorexia or weight loss. She was diagnosed as seropositive RA six years earlier and was treated with conventional DMARDs including methotrexate, sulfasalazine, and hydroxychloroquine, proven irresponsive to conventional DMARDs. Screening for TB including chest X-ray, TST, and QFT-G were performed before the infliximab therapy. TST was negative (induration < 3 mm) and QFT-G was negative (Nil, 0.06 IU/mL; TB response, 0.12 IU/mL; mitogen response, 13.35 IU/mL). Thus all the tests were negative, we started Infliximab therapy without TB prophylaxis. Infliximab therapy was continued for six months with an injection of 100-mg intravenous every other week, while the disease activity of RA has been decreased before admission.

Physical examination revealed ascites. Laboratory evaluation showed 4,600/mm³ white blood cells with 83% neutrophils and hemoglobin 12.8 g/dL. The erythrocyte sedimentation rate was 42 mm/hr and C-reactive protein was 6.80 mg/dL (normal, 0.1–0.8 mg/dL). Electrolytes, hepatic function tests, and renal function tests were within normal limits, while the serologic tests for antinuclear antibodies, hepatitis virus, and human immunodeficiency virus serology were all negative. Rheumatoid factor was positive (21.4 U/mL; normal, <20 U/mL). No organism was detected in blood cultures.

Chest X-ray revealed no active lung lesion. Abdominal computed tomography (CT) scan showed large amount of ascites, irregular peritoneal thickening, and omental nodules (Figure 1). Paracentesis yielded a turbid ascitic fluid with 1,120/mm³ white blood cells with 83% lymphocytes and elevated adenosine deaminase.

Figure 1. Large amount of ascites, peritoneal irregular thickening and omental nodules suggesting peritoneal tuberculosis in the abdomen computed tomography.

Figure 2. (A) Multiple granulomas surrounded by Langhans giant cells, and few lymphocytes and caseous necrosis (H&E stain, ×100). (B) Caseous necrosis and few lymphocytes in granuloma (H&E stain, ×400). A acid-fast bacillus is seen (inset: Ziehl-Neelsen stain, ×1,000).
(ADA) as 57.4 IU/L (normal, < 40 IU/L). Ascites culture for bacteria and M. tuberculosis and repeated cyto-
logica l results performed in ascitic fluid were negative. Sputum cultures were also negative for M. tuberculosis; Repeated TST converted positive (induration 18 mm) and QFT-G converted positive (Nil, 0.19 IU/mL; TB re-
sponse, 0.53 IU/mL; mitogen response, 6.87 IU/mL).

Laparoscopic biopsy was performed to make a con-
firmative diagnosis. There were widespread miliary
nodules on the peritoneal surfaces in which multiple bi-
opsies were performed. The histopathological examina-
tion revealed multiple foci of chronic granulomatous in-
flammation surrounded by Langhans-type giant cells, a
few lymphocytes, and a few caseous necroses. A few
acid-fast bacilli were present on Ziehl-Neelsen stain
(Figure 2).

Anti-TB therapy with isoniazid 300 mg/day, rifampin
600 mg/day, ethambutol 800 mg/day, and pyrazinamide
1,500 mg/day were implemented. After treatment in-
stauration, the abdominal distention with ascites de-
creased while the symptom improved. In the follow-up
abdominal CT scan, irregular peritoneal thickening and
omentum nodularity also decreased.

Discussion

TNF is a pro-inflammatory cytokine that plays a major
role in the pathogenesis of many autoimmune diseases,
especially RA. TNF blockers inhibit this pro-inflam-
matory pathway and decrease the disease activity of RA.
As a result, they improve the outcome of RA dramati-
cally and therefore they have emerged as a new treat-
ment of many autoimmune diseases. Despite the clinical
benefit, they also increase the risk of opportunistic in-
fec tions, especially TB17. Because TNF has the role of
making granuloma in the pathogenesis of TB, blocking
of TNF might make TB progress.

There are three types of TNF blockers, including chi-
meric monoclonal antibody (infliximab), human mono-
clonal antibody (adalimumab), and human fusion pro-
tein (etanercept). They have different effectiveness and
side effects due to their different mechanisms of action,
biology, or kinetics8. For the incidence of TB in patients
with RA and treated with anti-TNF therapy has some
differences between the used agents, 3- to 4-fold higher
with infliximab and adalimumab than etanercept, which
could be originated from the difference in the effective-
ness of TNF blockade between those agents2,9.

Most countries have established a guideline to screen
for TB before starting TNF blockers to prevent develop-
ing TB during treatment6. Because South Korea is classi-

cified as a country of intermediate TB burden8, pre-
vention and early diagnosis of TB could be very im-
portan t issue even at present. KFDA provided guide-
lines for screening and prophylaxis for latent TB prior
to TNF blocker trial. The guidelines recommend TST
and chest X-ray before TNF blocker treatment. Because
of the defective cellular immune function, inadequate
response to TST in RA could be possible8,10. In a TB-en-
demic population, the QFT-G seems to be a more accu-
rate test for detection of LTBI in RA patients compared
with the TST, and may potentially improve the targeting
of prophylactic therapy before treatment with anti-TNF
agents11.

In our case, despite the patient did TST and QFT-G,
the peritoneal TB developed within 6 months of in-
fliximab therapy. In South Korea, only two cases have
been reported on peritoneal TB in patients treated with
infliximab treatment12,13. One of them had RA and the
other had AS. Those patients tested only TST without
QFT-G before infliximab therapy and the diagnosis of
peritoneal TB was made by radiologic findings and as-
cites ADA results without adequate peritoneal biopsy.
Different with these cases, we did QFT-G to compen-
sate the TST. However, there is a limitation when per-
forming QFT-G on immunosuppressed patients. Be-
cause many rheumatoid arthritis patients may have been
given methotrexate or glucocorticoids, which suppress
the immune system prior to the administration of TNF
blocker, possibly making it difficult to interpret the
QFT-G results. In order to decrease the incidence of TB
during TNF blocker therapy, reinforcing the screening
test is important, but also follow-up monitoring test is
important. Until now, no guideline has been set to
monitor TB during the TNF blocker treatment. Although both TST and QFT-G previously tested as negative, some patients could get TB during the TNF blocker treatment and could show positive conversion to those tests even before active clinical manifestations. In one study, among the patients with rheumatic disease treated with TNF blockers, 32.6% of them showed positive conversion of TST during treatment. An estimated 14% of patients, who got QFT-G before, had positive conversion with follow-up test, and one of them developed miliary TB.

The development of TB could be the main reason that TNF blocker therapy should be terminated even in those patients who need TNF blocker such as refractory RA or other refractory autoimmune diseases, and stopping TNF blocker has an influence on the result of RA treatment in that clinical setting. Considering the clinical effects of newly developed TB including patients' discomfort, possible side effects of anti-TB medications and the cost for diagnosis and treatment of TB, the monitoring for TB during TNF blocker therapy, especially with infliximab or adalimumab is clinically important.

The three cases including our case, the peritoneal TB developed within 6 months after infliximab treatment. Usually, the median interval from the start of treatment with infliximab until the development of TB was less than six months. If we monitored TB by some tests within 6 months, we could prevent the development of peritoneal TB before patient's discomfort.

As a conclusion, although every patient who would undergo TNF blocking therapy for refractory autoimmune disease is under monitoring for TB before starting the treatment, there could be some cases who developed new TB infection during TNF blocker therapy. Therefore, there should be an agreement and consideration for making guidelines for monitoring TB in the patients who undergoing TNF blocker therapy.

References

1. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register, Rheumatology (Oxford) 2011;50: 196-203.
2. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowksi A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR), Ann Rheum Dis 2010;69:522-8.
3. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
4. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34: 706-11.
5. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med 2001;345:1088-104.
6. Kwok SK, Park SH. Guidelines for prevention of tuberculosis in patients with rheumatoid arthritis treated with TNF-alpha blockers. J Korean Rheum Assoc 2007; 14:105-11.
7. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
8. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293: 2756-61.
9. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection, Semin Arthritis Rheum 2006;36:159-67.
10. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with
rheumatoid arthritis: study in a population with a high prevalence of tuberculosis, Ann Rheum Dis 2005:64: 1360-1.

11. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al, Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population, J Rheumatol 2008;35:776-81.

12. Park H, Park CW, Kim KB, Lee MJ, Zeon SJ, Shim SC, et al, A case of peritoneal tuberculosis with Poncet's disease in a patient treated with infliximab, J Rheum Dis 2011:18:55-9.

13. Kim IT, Park HB, Lee SH, Hyun YK, Kim YJ, Lee YW, et al, Tuberculous peritonitis in a patient with rheumatoid arthritis treated with infliximab, J Rheum Dis 2011:18:320-3.

14. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH, Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial, J Rheumatol 2009;36:2158-65.